Tiefenbacher: Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority (SFDA)
Tiefenbacher: Own manufacturing and laboratory facilities successfully registered by the Saudi Food and Drug Authority (SFDA) for GCC region
The SFDA approves Tiefenbacher facilities! We are happy to announce that our manufacturing and laboratory facilities for oral solids at AET Laboratories in Hyderabad (India) have been successfully registered by the Saudi Food and Drug Authority (SFDA).
The registration is a great door opener for the full GCC region. The six Arab countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates) is an important addition to our existing European (EMA) and international certifications (like the US FDA approval) and follows Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER GROUP is committed to becoming climate neutral
Tiefenbacher Group is committed to becoming climate neutral by the end of 2025
We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of patients worldwide, we recognize the importance of taking action to address the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy that includes the following measures, among others:
As our biggest driver of the carbon footprint is energy consumption, large-scale solar panels will be installed on our manufacturing facilities in Cyprus and India. Any electricity that cannot be produced in-house and must be purchased will be purely green electricity. In addition, we are implementing energy saving and efficiency measures – especially at our production sites. Furthermore, all company vehicles will be exclusively electric in the future. With these measures, we will already achieve a great interim goal: reducing our emissions by 80% by January 2024.
We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the coming months and years.
*Scope 1 and 2 according to GHG as well as business travel and employee commuting
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
Tiefenbacher: Renovating Headquarters in Hamburg
Tiefenbacher Pharmaceutical, a part of Tiefenbacher Group:
Renovating Headquarters in Hamburg /Germany – an agile, open-plan work space
Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany as a response to the novel ways of working? We are excited to share the first results of the restructuring and are pleased to bring the first changes to life. The newly designed building will be a modern and innovative workspace that reflects our culture of entrepreneurship, professional excellence, and openness. The open-floor concept promotes creativity, collaboration, and teamwork among our employees. Also, the office concept provides for a maximum democratic approach in all the rooms, including the management stuff rooms. Additionally, the modernization allowed us for the new branding elements to be incorporated into the workspace. We believe that the new space, right on the banks of the river Elbe, provides a great working environment that supports the growth and wellbeing of our employees at the same time. With hybrid and at-home work the new normal for many people, Tiefenbacher wants to keep its workspace relevant and up to date.
Watch our short video to see the first changes with our new flexible work space. The interior turned out to be generally airy, transparent, filled with light. We´ll keep you posted on the progress and look forward to welcoming you to our new office space soon! The full modernization at our headquarters is expected to be completed in 2024.
TIEFENBACHER PHARMACEUTICALS AT DCAT 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group – at DCAT 2023: Thanks for meeting us in New York City!
DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions at DCAT 2023!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms (FDF) and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals New market launch: antihistamine Bilastine
New Market Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in Germany
The allergy season is starting. Therefore we at Tiefenbacher Pharmaceuticals are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
Bilastine is an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria. It belongs to the non-sedating second-generation antihistamines. Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending. The 20 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories. This product is currently marketed by our partner, a well-known international pharmaceutical company.
With this market entry we enable patients in Germany a better access to an important medicine. Moreover, it’s currently the only product of this type available in pharmacies without a prescription needed. Further generic launches in European markets are planned soon. Tiefenbacher Pharmaceuticals is committed to continuously making high-quality medicines better affordable, better global availability, and better than before.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms including highly potent drugs and e-healthcare solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER GROUPS: Registration of manufacturing sites by UAE Ministry of Health
Tiefenbacher manufacturing sites have been successfully registered by the United Arab Emirates Ministry of Health
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health!
The United Arab Emirates (UAE) comprises seven Emirates located in the south east of the Arabian Peninsula: Abu Dhabi, Dubai, Sharjah, Ajman, Ras Al Khaimah, Umm al-Qaiwain and Fujairah. The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals: World Cancer Day 2023
Tiefenbacher Pharmaceuticals marks 'World Cancer Day 2023' to increase awareness prevention throughout media together
TIEFENBACHER joined to harness the power of social media to raise awareness on cancer early detection and prevention, support cancer survivors and build cancer care capacity for people. These efforts are a contribution to reduce the global burden of cancer.
“World Cancer Day every 4 February is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awarness, we collective resonate against the cancer burden in the world. Cancer has a global impact of around 20 million new cases each year, remaining a major public health challenge. In the fight against this disease, we at TIEFENBACHER are committed to delivering better affordable medicines for cancer patients around the world. Hereby we are always aiming to improve patients’ lives by developing added value medicines with a better posology, additional strengths, suitable fixed dosage combinations, or personalized therapies by combining medicines with smart e-health solutions – just to name a few of our differentiated and innovative product solutions. TIEFENBACHER PHARMACEUTICALS has already 25 leading highly potent cancer drugs in its launch pipeline which are planned to be developed and manufactured in our new state-of-the-art high potent facilities in Hyderabad, India.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER PHARMACEUTICALS WISHES A HEALTHY NEW YEAR 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group:
Health New Year 2023
From all over the world, we wish you a happy and healthy New Year 2023!
In order to serve more than 80 national markets in the best possible way for our partners, we are particularly proud to have so many different nationalities and cultures at TIEFENBACHER GROUP. Watch our colleagues from our various locations sharing short New Year’s greetings in their respective national languages with you.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals generic launch: Psoriasis medication Apremilast
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the psoriasis medication Apremilast in Canada
We at Tiefenbacher Pharmaceuticals strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada. With the same safety and efficacy profile as the brand-name product, Apremilast is approved by the U.S Food and Drug Administration (FDA) and available at a lower cost.
Apremilast is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers. We are standing out in launching the only generic version of Apremilast in the form of a starter kit (10 mg, 20 mg, and 30 mg) additionally to bottles of 30 mg tablets. This allows the product to be taken gradually to the recommended dosage, facilitating the work of physicians and pharmacists and improving the patient experience. The product has been developed and produced in TIEFENBACHER GROUP´s own state-of-the-art facilities in India and is marketed by our partner, a well-established Canadian pharmaceutical company. With this early market entry Tiefenbacher Pharmaceuticals achieves significant savings for the international health care systems and enables patients in Canada a better affordable access to a life-improving treatment.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER PHARMACEUTICALS New market launch: Abiraterone/Prednisolone
Tiefenbacher Pharmaceuticals successfully launches generic versions of Abiraterone and value-added product Abiraterone/Prednisolone, Prostate Cancer
We at Tiefenbacher Pharmaceuticals aim to improve peoples´ lives around the world by making medicines better affordable, better available, and better than before! That´s why we are excited to share that Tiefenbacher Pharmaceuticals has successfully prepared the launch of the generic versions of Abiraterone and the value-added product of Abiraterone/Prednisolone for a market entry in Europe.
For the mono product Abiraterone, we were able to achieve a day one launch after patent expiration, making this important therapy finally more affordable for patients around the world. With the combination product Abiraterone/Prednisolone we offer a value-added product which comes in a special combi blister packaging improving patients´ compliance, physicians´ convenience, and protecting the environment.
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners. We will keep you updated about launches of this and other products in further international markets.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information about our finished dosage forms including highly potent drugs and e-healthcare solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com